# Liu Chuanwen

> Liu Chuanwen is a Series A investor at Neovision Capital backing Biotechnology and Medical Device. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Neovision Capital](https://shizune.co/investors/profile/neovision-capital)
- Total investments: 1
- Last investment: Jul 2023
- Lead investor: 100%
- Last updated: Aug 2026

Liu Chuanwen is a Series A investor at Neovision Capital focused on Biotechnology and Medical Device. Liu Chuanwen is the managing director of Hi-Tech Xinjun.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 1 | 100% |
| Medical Device | 1 | 100% |
| Information Technology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Media Center | Media Center is a technology-based corporation that uses technological innovation to boost industrial upgrading. It enables biotechnology and the bioindustry, the employs automation, artificial intelligence, big data, and industrial Internet technologies. Robot scientists free human scientists' hands, unleash their creativity, and raise thetime and life value of mental workers, intelligent parallel bioreactors accelerate the R&D cycle, save laboratory space, and reduce R&D costs. | $1.4M | Series A | Jul 06, 2023 |  |

1 of 1 investments shown.

## About Neovision Capital

VC Fund · Shanghai, China

Neovision Capital was founded in 2015. Key founders are from Costone Capital, J.P. Morgan and so on. Leveraging its core team’s rich China-operational experiences, international resources, and business acumen, we are actually dedicated to both early and growth-stage investment in healthcare and TMT sector in China. In order to leverage our coreassets, we actively contribute expertise in essential services including branding, marketing, channel development, overseas expansion, human resources, and finance.

2 contacts available at Neovision Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Liu Chuanwen | Managing Director | https://shizune.co/investors/profile/liu-chuanwen |
| Qin Yangwen | Managing partner | https://shizune.co/investors/profile/qin-yangwen |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Liu Chuanwen invest in?

Liu Chuanwen invests primarily in Biotechnology, Medical Device and Information Technology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Liu Chuanwen last invest?

The most recent investment recorded for Liu Chuanwen closed in Jul 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co